Treprostinil diolamine
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414605

CAS#: 830354-48-8 (diolamine)

Description: Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a chemically stable prostacyclin analog. Its principal pharmacologic action is direct vasodilation, which causes reduction of pulmonary and systemic arterial pressure, reducing right and left ventricular afterload; therefore improves the cardiac output. It also has an antiplatelet effect.

Chemical Structure

img
Treprostinil diolamine
CAS# 830354-48-8 (diolamine)
Instruction

Theoretical Analysis

MedKoo Cat#: 414605
Name: Treprostinil diolamine
CAS#: 830354-48-8 (diolamine)
Chemical Formula: C27H45NO7
Exact Mass: 495.32
Molecular Weight: 495.660
Elemental Analysis: C, 65.43; H, 9.15; N, 2.83; O, 22.59

Price and Availability

Size Price Availability Quantity
50mg USD 750 2 Weeks
100mg USD 1350 2 Weeks
200mg USD 2350 2 Weeks
500mg USD 3850 2 Weeks
Bulk inquiry

Related CAS #: 289480-64-4 (sodium)   81846-19-7 (free acid)   830354-48-8 (diolamine)    

Synonym: Treprostinil diolamine; UT-15C; UT15C; UT 15C

IUPAC/Chemical Name: 2-((1R,2R,3aS,9aS)-2-Hydroxy-1-(3(S)-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta(b)naphthalen-5-yloxy)acetic acid diethanolamine salt

InChi Key: RHWRWEUCEXUUAV-ZSESPEEFSA-N

InChi Code: InChI=1S/C23H34O5.C4H11NO2/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25;6-3-1-5-2-4-7/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27);5-7H,1-4H2/t16-,17-,18+,19-,21+;/m0./s1

SMILES Code: OCC[NH2+]CCO.O=C([O-])COC1=CC=CC2=C1C[C@]3([H])[C@]([C@@H](CC[C@@H](O)CCCCC)[C@H](O)C3)([H])C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 495.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fang L, Chen WC, Jaksch P, Molino A, Saglia A, Roth M, Lambers C. Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells. Int J Mol Sci. 2023 Jul 29;24(15):12148. doi: 10.3390/ijms241512148. PMID: 37569523; PMCID: PMC10418929.


2: Parikh R, O'Sullivan DM, Farber HW. The PH-ILD Detection tool: External validation and use in patients with ILD. Pulm Circ. 2023 Aug 8;13(3):e12273. doi: 10.1002/pul2.12273. PMID: 37564922; PMCID: PMC10410234.


3: Schramm JE, Dykes JC, Hopper RK, Feinstein JA, Rosenthal DN, Kameny RJ. Pulmonary Vasodilator Therapy in Pediatric Patients on Ventricular Assist Device Support: A Single-Center Experience and Proposal for Use. ASAIO J. 2023 Aug 9. doi: 10.1097/MAT.0000000000002023. Epub ahead of print. PMID: 37556563.


4: Harutyunova S, Benjamin N, Eichstaedt C, Marra AM, Xanthouli P, Nagel C, Grünig E, Egenlauf B. Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension. Respiration. 2023 Aug 4:1-12. doi: 10.1159/000531169. Epub ahead of print. PMID: 37544296.


5: Miller CE, Franco V, Smith JS, Balasubramanian V, Kingrey J, Zolty R, Melendres-Groves L, Huston J, Elwing JM, Ravichandran A, Cella D, Shen E, Seaman S, Thrasher CM, Broderick M, Oudiz RJ. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respir Med. 2023 Aug 1;218:107374. doi: 10.1016/j.rmed.2023.107374. Epub ahead of print. PMID: 37532157.


6: Miyanaga S, Kubota K, Iwatani N, Akao M, Mitsuyoshi K, Ohishi M. Pulmonary artery hypertension-associated with human immunodeficiency virus infection with attenuated effect of subcutaneous treprostinil injection during long-term observation: A case report. J Cardiol Cases. 2023 Jun 1;28(2):72-74. doi: 10.1016/j.jccase.2023.04.008. PMID: 37521577; PMCID: PMC10382956.


7: Kingrey JF, Miller CE, Franco V, Smith JS, Zolty R, Oudiz RJ, Elwing JM, Huston JH, Melendres-Groves L, Ravichandran A, Balasubramanian V, Wu B, Hwang S, Seaman S, Broderick M, Rahaghi FF. Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil. Pulm Circ. 2023 Jul 25;13(3):e12255. doi: 10.1002/pul2.12255. PMID: 37497167; PMCID: PMC10368085.


8: Blanco I, Hernández-González F, García A, Torres-Castro R, Barberà JA. Management of Pulmonary Hypertension Associated with Chronic Lung Disease. Semin Respir Crit Care Med. 2023 Jul 24. doi: 10.1055/s-0043-1770121. Epub ahead of print. PMID: 37487524.


9: West N, Smoot K, Patzlaff N, Miceli M, Waxman A. Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease. Future Cardiol. 2023 Apr;19(5):229-239. doi: 10.2217/fca-2022-0108. Epub 2023 Jul 19. PMID: 37466095.


10: Coons JC, Empey PE. Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives. Pharmgenomics Pers Med. 2023 Jul 11;16:729-737. doi: 10.2147/PGPM.S361222. PMID: 37457231; PMCID: PMC10349598.


11: Lachant D, Minkin R, Swisher J, Mogri M, Zolty R, Hwang S, Seaman S, Broderick M, Sahay S. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry. Pulm Pharmacol Ther. 2023 Jul 13;82:102232. doi: 10.1016/j.pupt.2023.102232. Epub ahead of print. PMID: 37451609.


12: Abu-Hanna J, Anastasakis E, Patel JA, Eddama MMR, Denton CP, Taanman JW, Abraham D, Clapp LH. Prostacyclin mimetics inhibit DRP1-mediated pro- proliferative mitochondrial fragmentation in pulmonary arterial hypertension. Vascul Pharmacol. 2023 Aug;151:107194. doi: 10.1016/j.vph.2023.107194. Epub 2023 Jul 11. PMID: 37442283.


13: Carbone RG, Monselise A, Puppo F. Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease: Is All Clear? Chest. 2023 Jul;164(1):e21. doi: 10.1016/j.chest.2023.04.015. PMID: 37423704.


14: Cottin V, Diesler R, Turquier S, Valenzuela C. Interstitial lung disease- associated pulmonary hypertension - what the future holds. Curr Opin Pulm Med. 2023 Sep 1;29(5):406-415. doi: 10.1097/MCP.0000000000000992. Epub 2023 Jul 7. PMID: 37417835.


15: Cottin V, Valenzuela C, Humbert M. Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud. Eur Respir J. 2023 Jun 29;61(6):2300944. doi: 10.1183/13993003.00944-2023. PMID: 37385654.


16: Brewer J, Kimber A. Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report. Front Med (Lausanne). 2023 Jun 13;10:1188083. doi: 10.3389/fmed.2023.1188083. PMID: 37384049; PMCID: PMC10293745.


17: Fabyan KD, Chandel A, King CS. Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care. Curr Pulmonol Rep. 2023 May 22:1-8. doi: 10.1007/s13665-023-00311-2. Epub ahead of print. PMID: 37362782; PMCID: PMC10200699.


18: Avitabile CM, Flohr S, Mathew L, Wang Y, Ash D, Frank DB, Tingo JE, Rintoul NE, Hedrick HL. Quantitative Measures of Right Ventricular Size and Function by Echocardiogram Correlate with Cardiac Catheterization Hemodynamics in Congenital Diaphragmatic Hernia. J Pediatr. 2023 Jun 15;261:113564. doi: 10.1016/j.jpeds.2023.113564. Epub ahead of print. PMID: 37329980.


19: Ting YH, Yu MW, Wu YJ, Wu SH. Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report. Acta Cardiol Sin. 2023 May;39(3):492-496. doi: 10.6515/ACS.202305_39(3).20230130A. PMID: 37229336; PMCID: PMC10203720.


20: Wiedenroth CB, Pruefer D, Adameit MSD, Mayer E, Guth S. Chronic thromboembolic pulmonary hypertension-medical, interventional, and surgical therapy. Herz. 2023 Aug;48(4):280-284. English. doi: 10.1007/s00059-023-05172-8. Epub 2023 Apr 25. PMID: 37186021.